Novartis Talks Up Potential Blockbusters
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis used its second-quarter results to flag the blockbuster potential of three drugs: recently-approved heart failure drug Entresto, first-to-be approved IL-17a blocker Cosentyx - as well as oncology drug Promacta, which it bought from GSK earlier this year.
You may also be interested in...
Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval
Reimbursement complexity and physician reluctance to move stable patients off their current treatment regimens are the biggest hurdles.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.